Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Aldeyra Therapeutics
AddedFeb 17, 2024
UpdatedJul 5, 2026
Aldeyra Therapeutics

Aldeyra Therapeutics

Aldeyra Therapeutics develops treatments for age-related macular degeneration, aiming to prevent blindness.

HQ
Burlington, MA, US
Founded
2004
Overview
Compare
Fundraising
Employees

Aldexa Therapeutics, now known as Aldeyra Therapeutics, develops treatments for age-related macular degeneration, focusing on preventing blindness. Founded in 2004 and based in Burlington, Massachusetts, the company creates drugs to inhibit toxic metabolites in the eye.

Aldeyra Therapeutics has made significant strides in ophthalmology, contributing to advancements in treating eye diseases. Their innovative approach has positioned them as a key player in the market, impacting patient care and eye health significantly.

Aldeyra Therapeutics - Similar Companies

Aldena Therapeutics logo

Aldena Therapeutics

Aldea Pharmaceuticals logo

Aldea Pharmaceuticals

Seeing Medicines logo

Seeing Medicines

EyeCyte logo

EyeCyte

eyecyte.com

OcuCure Therapeutics logo

OcuCure Therapeutics

Allyx Therapeutics logo

Allyx Therapeutics

allyxthera.com

Exalys Therapeutics logo

Exalys Therapeutics

Oculogenex logo

Oculogenex

oculogenex.com

Alkeus Pharmaceuticals logo

Alkeus Pharmaceuticals

alkeus.com

Vision Medicines logo

Vision Medicines

Ocular Therapeutix logo

Ocular Therapeutix

ocutx.com

Ocudyne logo

Ocudyne

ocudyne.com

Alimera Sciences logo

Alimera Sciences

Visiox logo

Visiox

visioxpharma.com

Macuclear logo

Macuclear

Aldeyra Therapeutics - Quick Facts

Who are Aldeyra Therapeutics' competitors?

Companies similar to Aldeyra Therapeutics include Aldena Therapeutics, Aldea Pharmaceuticals, Seeing Medicines and EyeCyte.

When was Aldeyra Therapeutics founded?

Aldeyra Therapeutics was founded in 2004.

Where is Aldeyra Therapeutics' headquarters located?

Aldeyra Therapeutics' headquarters is located in Burlington, MA, US.

When was Aldeyra Therapeutics' last funding round?

Aldeyra Therapeutics' most recent funding round was for $4.8M (USD) in January 2013.

How much has Aldeyra Therapeutics raised to-date?

As of Jan 3, 2013, Aldeyra Therapeutics has raised a total of $4.8M (USD).

How many employees does Aldeyra Therapeutics have?

Aldeyra Therapeutics has 5 employees as of Feb 4, 2024.

Aldeyra Therapeutics - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Eye Disease Treatments
Tags
  • Healthtech
Unique IDs
  • secCik: 0001341235
  • ticker: ALDX
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 12 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified